Published April 1986
by S. Karger AG (Switzerland) .
Written in English
|The Physical Object|
|Number of Pages||268|
Symposium on Low-Dose Methotrexate Therapy in Rheumatic Diseases, Schloss Hugenpoet/Düsseldorf, September , ; volume editor, R. Rau. Reviews User-contributed reviews. Methotrexate at low doses (5–25 mg/week) is first‐line therapy for rheumatoid arthritis. However, there is inter‐ and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and by: 3. Background: Methotrexate is a second-line anti-inflammatory agent used in the treatment of rheumatic diseases. At low doses ( mg/week), it is associated with few serious side effects. Methods: Twenty-two patients (5 men, 17 women) with chronic noninfectious ocular inflammatory disease, who had not responded to or who had become intolerant of . As a result, its uses have widened to other inflammatory rheumatic and nonrheumatic conditions, often in a role as a corticosteroid-sparing agent. Experimentation, largely by dermatologists, led to the low-dose, weekly, oral or intramuscular methotrexate therapy now used for rheumatic diseases.
Severity of myelosuppression related to low-dose MTX therapy for inflammatory rheumatic diseases As shown in Table 2, among the 40 cases of myelosuppression related to low-dose MTX therapy, 31 cases (%) were pancytopenia, 8 (20%) were bicytopenia (three cases, leukopenia and thrombocytopenia; three cases, leukopenia and anemia; two cases. 1. Introduction. Methotrexate (MTX) is recommended as the first-line disease-modifying antirheumatic drug (DMARD) by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) [1, 2] in the treatment of rheumatoid arthritis (RA).Patients with RA tend to stay on MTX for years, making its long-term safety profile a . MTX was the first disease‐modifying anti‐rheumatic drug (DMARD) for most of the patients (87%) and the mean maximum dose of MTX was mg/wk (range ‐25). All patients were treated with folic acid. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. Discussion. Evidence is accumulating that low-dose methotrexate is an effective therapy to control RA refractory to more conventional treatment. 1 Common adverse reactions from low-dose methotrexate treatment include an increase in serum transaminase activity, nausea, and diarrhea. 1 The incidence of interstitial pneumonitis is lower than 5 percent in the patients receiving this low-dose.
Overall it is very well tolerated, with a low incidence of bone marrow suppression. 1,2 In a study of patients with rheumatoid arthritis, Grove et al found methotrexate to be the best tolerated of the disease modifying antirheumatic drugs. 3 A recent prospective study found that methotrexate may improve survival in patients with rheumatoid. The American College of Rheumatology estimates that million Americans are affected by rheumatoid arthritis. These patients are usually women between 30 and 50 years of age, but anyone can develop rheumatoid arthritis at any age. Different types of medications, including methotrexate and low dose prednisone, are used to treat rheumatoid arthritis. In rheumatoid arthritis (RA) and other disorders, MTX is administered as long-term, low-dose therapy, usually to 25 mg weekly, unlike its use for treatment of malignant disease, where it is may be administered in a cyclic fashion in doses of 1 gram or more. Objective Severe myelosuppression is a serious concern in the management of rheumatic disease patients receiving methotrexate (MTX) therapy. This study was intended to explore factors associated with the development of MTX-related myelosuppression and its disease severity. Methods We retrospectively examined a total of 40 cases of MTX-related .